Recombinant Human Peroxisome proliferator-activated receptor alpha (PPARA)

In Stock
Code CSB-BP018421HU
MSDS
Size $528
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Based on the SEQUEST from database of Baculovirus host and target protein, the LC-MS/MS Analysis result of CSB-BP018421HU could indicate that this peptide derived from Baculovirus-expressed Homo sapiens (Human) PPARA.
  • Based on the SEQUEST from database of Baculovirus host and target protein, the LC-MS/MS Analysis result of CSB-BP018421HU could indicate that this peptide derived from Baculovirus-expressed Homo sapiens (Human) PPARA.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 85% as determined by SDS-PAGE.
Target Names
PPARA
Uniprot No.
Research Area
Cancer
Alternative Names
hPPAR; MGC2237; MGC2452; NR1C1; Nuclear receptor subfamily 1 group C member 1; OTTHUMP00000197740; OTTHUMP00000197741; Peroxisome proliferative activated receptor alpha; Peroxisome proliferator activated receptor alpha; Peroxisome proliferator-activated receptor alpha; PPAR; PPAR-alpha; ppara; PPARA_HUMAN; PPARalpha
Species
Homo sapiens (Human)
Source
Baculovirus
Expression Region
1-468aa
Target Protein Sequence
MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSCPGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACEGCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSEKAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
56.2 kDa
Protein Length
Full Length
Tag Info
N-terminal 10xHis-tagged and C-terminal Myc-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

The recombinant Human PPARA was expressed with the amino acid range of 1-468. The expected molecular weight for the PPARA protein is calculated to be 56.2 kDa. This protein is generated in a baculovirus-based system. The N-terminal 10xHis tag and C-terminal Myc tag was fused into the coding gene segment of PPARA, making it easier to detect and purify the PPARA recombinant protein in the later stages of expression and purification.

PPARA (Peroxisome proliferator-activated receptor alpha) is a nuclear receptor playing a crucial role in energy and lipid metabolism. Research primarily focuses on two major areas. Firstly, the role of PPARA in lipid metabolism regulation is widely studied. Researchers delve into the regulatory mechanisms of PPARA in fatty acid oxidation, activation of brown adipose tissue, cholesterol metabolism, providing new insights into the treatment of metabolic diseases like diabetes and hyperlipidemia. Secondly, the physiological functions of PPARA in tissues such as the liver and heart have attracted considerable attention. Researchers are attentive to PPARA's regulatory role in liver lipid metabolism, cardiac protection, and its involvement in metabolism-related inflammatory responses.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.
Gene References into Functions
  1. Ubiquitination modification through the coordinated action of PAQR3 with HUWE1 plays a crucial role in regulating the activity of hepatic PPARalpha in response to starvation. PMID: 29331071
  2. Circulated eosinophilic expression of PPARalpha protein is reduced in metabolic syndrome. PMID: 29699951
  3. TNFalpha differently regulated the levels of PPARalpha, LXRalpha, and LXRbeta binding to the apoA-I gene promoter in THP-1 cells. Obtained results suggest a novel tissue-specific mechanism of the TNFalpha-mediated regulation of apoA-I gene in monocytes and macrophages and show that endogenous ApoA-I might be positively regulated in macrophage during inflammation. PMID: 29442267
  4. MAR1 ameliorates LPS-induced atherosclerotic reactions via PPARalpha-mediated suppression of inflammation and ER stress. PMID: 29971543
  5. Data suggest that, in hepatocytes, MIRN34A plays roles in regulation of mitochondrial remodeling and lipid metabolism including development/prevention of non-alcoholic fatty liver disease; MIRN34A appears to act via AMPK/PPARalpha signal transduction. (MIRN34A = microRNA 34a; AMPK = AMP-activated protein kinase; PPARalpha = peroxisome proliferator activated receptor alpha) PMID: 29197627
  6. miR-214 overexpression inhibits glioma cell growth in vitro and in vivo by inducing cell cycle arrest in G0/G1. Collectively, these data uncover a novel role for a PPARalpha-miR-214-E2F2 pathway in controlling glioma cell proliferation. PMID: 29862267
  7. Improvements in metabolic and neurodegenerative diseases are often attributed to anti-inflammatory effects of PPAR activation. (Review) PMID: 29799467
  8. circRNA_0046366, which demonstrated expression loss in HepG2-based hepatocellular steatosis, exerts antagonistic effect on miR-34a activity. miR-34a inactivation abrogates its inhibitory role against PPARalpha. PMID: 29391755
  9. We first reported that the FOMX1 pathway is the most upregulated and the PPARalpha pathway is the most downregulated pathway in Triple Negative Breast Cancers (TNBCs). These two pathways could be simultaneously targeted in further studies. Also the pathway classifier we performed in this study provided insight into the TNBC heterogeneity. PMID: 29301506
  10. Polymorphism of PPARA is associated with late onset of type 2 diabetes mellitus. PMID: 28292576
  11. results demonstrated that OEA exerts anti-inflammatory effects by enhancing PPARalpha signaling, inhibiting the TLR4-mediated NF-kappaB signaling pathway, and interfering with the ERK1/2-dependent signaling cascade (TLR4/ERK1/2/AP-1/STAT3), which suggests that OEA may be a therapeutic agent for inflammatory diseases. PMID: 27721381
  12. data suggested that miR-19a negatively controlled the autophagy of hepatocytes attenuated in D-GalN/LPS-stimulated hepatocytes via regulating NBR2 and AMPK/PPARalpha signaling. PMID: 28586153
  13. The minor allele of rs1800206 and rs1805192 from PPAR A and PPAR G and its interaction were associated with increased Breast Cancer risk. PMID: 28669518
  14. High concentrations of DINCH urinary metabolites activate human PPAR-alpha. PMID: 29421333
  15. PPARalpha is overexpressed in primary glioblastoma PMID: 27926792
  16. these results suggest that the E2F1/miR19a/PPARalpha feedback loop is critical for glioma progression PMID: 27835866
  17. Data conclude that the ER-stress mediated reduction in apoA-I transcription could be partly mediated via the inhibition of PPARalpha mRNA expression and activity. In addition, BET inhibition increased apoA-I transcription, even if PPARalpha production and activity were decreased. Both BET inhibition and PPARalpha activation ameliorate the apoA-I lowering effect of ER-stress and are therefore interesting targets to elev... PMID: 28012209
  18. Results demonstrated that PPARa directly inhibited Glut1 mRNA expression resulting in influx of glucose in cancer cells. PMID: 27918085
  19. PPARalpha and LXRalpha may be mediators by which omega3PUFA attenuate bile acid-induced hepatocellular injury PMID: 26756785
  20. Our results support an important association between rs1800206 minor allele of PPAR alpha and diabetic retinopathy, and the interaction analysis also shown a combined effect of Leu162 allele-abdominal obesity interaction on diabetic retinopathy. PMID: 26671228
  21. Taken together, our data suggest that eupatilin inhibits TNFalpha-induced MMP-2/-9 expression by suppressing NF-kappaB and MAPKAP-1 pathways via PPARalpha. Our findings suggest the usefulness of eupatilin for preventing skin aging. PMID: 28899779
  22. Hepatic PARP1 activation inhibits FAO pathway upregulation through poly(ADP-ribosyl)ation of PPARalpha, worsening hepatic steatosis and inflammatory responses associated with overnutrition. PMID: 27979751
  23. Aleglitazar protects cardiomyocytes against hyperglycaemia-induced apoptosis by combined activation of both peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma. PMID: 28111985
  24. Study reports a molecular mechanism by which glucocorticoid-induced PPARalpha expression negatively affects the activity of PPARgamma and downregulates BCO1 gene expression. Results explicate novel aspects of local glucocorticoid:retinoid interactions that may contribute to alveolar tissue remodeling in chronic lung diseases that affect children and, possibly, adults. PMID: 28732066
  25. Interference with PLIN2 and PPARalpha resulted in major alterations in gene expression, especially affecting lipid, glucose, and purine metabolism. PMID: 27308945
  26. PPARalpha and FXR function coordinately to integrate liver energy balance. PMID: 28287408
  27. This study showed that oleoylethanolamine and palmitoylethanolamine have endogenous roles and potential therapeutic applications in conditions of intestinal hyperpermeability and inflammation. PMID: 27623929
  28. An association was found with PPARalpha polymorphism and patients with nicotine dependency and schizophrenia. PMID: 27624431
  29. PPAR agonists have shown to have anti proliferative effect in squamous cell carcinoma of the head and neck. PMID: 27896820
  30. Results show that PPARalpha is downregulated and SREBP-1c is upregulated in steatosis L-02 cells. These changes increase lipid synthesis and reduce lipid disposal, which ultimately lead to hepatic steatosis. PMID: 27270405
  31. Perfluoroalkyl acids addition to activating PPARalpha as a primary target, also have the potential to activate CAR, PPARgamma, and ERalpha as well as suppress STAT5B. PMID: 28558994
  32. the metabolic events, controlled by PPARs, occurring during neuronal precursor differentiation, the glucose and lipid metabolism was investigated. PMID: 27860527
  33. The CYP2E1-PPARalpha axis may play a role in ethanol-induced neurotoxicity via the alteration of the genes related with synaptic function PMID: 28385499
  34. Studies indicate that natural dietary compounds, including nutrients and phytochemicals, are Peroxisome proliferator-activated receptor alpha (PPARalpha) ligands or modulators. PMID: 27863018
  35. Genome-wide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARalpha in primary human hepatocytes has been presented. PMID: 26994748
  36. Hepatitis B virus increases the expression of alpha-mannosidases both in vitro and in vivo via activation of the PPARalpha pathway by its envelope protein. PMID: 27920474
  37. These observations candidate PPARs as new biomarkers of follicle competence opening new hypotheses on controlled ovarian stimulation effects on ovarian physiology. PMID: 26332656
  38. PPARalpha activation plays defensive and compensative roles by reducing cellular toxicity associated with fatty acids and sulfuric acid. PMID: 27644403
  39. PPARalpha/gamma agonist, elafibranor resolves nonalcoholic steatohepatitis without worsening fibrosis. PMID: 26874076
  40. The effects of fenofibrate on nonalcoholic fatty liver disease in the context of PPAR-alpha activation was studied. PMID: 27930988
  41. PPARA polymorphism is associated with the risk of coronary heart disease. PMID: 27512842
  42. Telmisartan improved the hyperglycemia-induced cardiac fibrosis through the PPARdelta/STAT3 pathway. PMID: 27519769
  43. A modest relationship was found between PPARalpha and AIP expression, both being significantly higher in the presence of pre-operative somatostatin analogues in somatotropinoma patients. PMID: 26872613
  44. Fenofibrate inhibited atrial metabolic remodeling in atrial fibrillation (AF) by regulating the PPAR-alpha/sirtuin 1/PGC-1alpha pathway indicating a novel therapeutic strategy for AF PMID: 26787506
  45. PPAR delta + 294TT genotype frequency in the Chinese Han population was higher than in the Chinese Uyghur population and may affect the risk of ischemic stroke. PMID: 26814631
  46. PPARalpha functions as an E3 ubiquitin ligase to induce Bcl2 ubiquitination and degradation, leading to increased cancer cell sensitivity in response to chemotherapy drugs. PMID: 26556865
  47. There was no statistically significant difference in the distribution of PPARalpha Leu162Val polymorphism between the ischemic stroke patients and controls in the Han ethnic group. PMID: 26671025
  48. results support an important association between rs1800206 minor allele (V) of PPAR alpha and lower CRP level; the interaction analysis showed a combined effect between rs1800206 and rs135539 on the lower CRP level PMID: 26497374
  49. PPAR-gamma and PTEN expressions are related to the clinical parameters and prognosis of renal cell carcinoma PMID: 26722456
  50. Describe a renoprotective role of fenofibrate in albumin bound fatty acid associated tubular toxicity, involving the transcriptional activation of PPARalpha and suppression of NF-kB. PMID: 26617775

Show More

Hide All

Subcellular Location
Nucleus.
Protein Families
Nuclear hormone receptor family, NR1 subfamily
Tissue Specificity
Skeletal muscle, liver, heart and kidney. Expressed in monocytes.
Database Links

HGNC: 9232

OMIM: 170998

KEGG: hsa:5465

STRING: 9606.ENSP00000262735

UniGene: Hs.103110

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*